18-22171415-C-T
Variant summary
Our verdict is Benign. Variant got -7 ACMG points: 0P and 7B. BP4_ModerateBP6BS2
The NM_005257.6(GATA6):c.271C>T(p.Pro91Ser) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000246 in 1,589,650 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. 12/20 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_005257.6 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -7 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.000171 AC: 26AN: 151960Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.000112 AC: 23AN: 204928Hom.: 0 AF XY: 0.000122 AC XY: 14AN XY: 114480
GnomAD4 exome AF: 0.000254 AC: 365AN: 1437580Hom.: 1 Cov.: 31 AF XY: 0.000250 AC XY: 179AN XY: 714800
GnomAD4 genome AF: 0.000171 AC: 26AN: 152070Hom.: 0 Cov.: 32 AF XY: 0.000188 AC XY: 14AN XY: 74338
ClinVar
Submissions by phenotype
Pancreatic hypoplasia-diabetes-congenital heart disease syndrome Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Pittsburgh Clinical Genomics Laboratory, University of Pittsburgh Medical Center | Apr 07, 2023 | This sequence variant is a single nucleotide substitution (C>T) at coding position 271 of the GATA6 gene that results in a proline to serine amino acid change at residue 91 of the GATA6 protein. This is a previously reported variant (ClinVar) that has been observed in an individual affected by atrial fibrillation (PMID: 27756709). This variant is present in 29 of 236,226 (0.01%) alleles gnomAD population database. Multiple bioinformatic tools provide conflicting predictions concerning the effect of this variant, and the proline residue at this position is moderately conserved across the vertebrate species examined. A transactivation study found that this variant increases the expression of some, but not all, of GATA6's downstream targets (PMID: 27756709). At this time, there is insufficient evidence to determine if this variant is pathogenic or benign. Therefore, we consider this a variant of uncertain significance. ACMG Criteria: - |
Uncertain significance, criteria provided, single submitter | clinical testing | Center for Genomic Medicine, King Faisal Specialist Hospital and Research Center | Sep 22, 2024 | - - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Jun 14, 2023 | Identified in a patient with early-onset atrial fibrillation (Tucker et al., 2017); Published in vitro functional studies suggest this variant results in increased expression of GATA6 target genes, NPPA and aMHC (Tucker et al., 2017); however, additional studies are needed to clarify the effect of this variant in vivo; In silico analysis supports that this missense variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 27756709) - |
Atrioventricular septal defect 5 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 28, 2023 | This sequence change replaces proline, which is neutral and non-polar, with serine, which is neutral and polar, at codon 91 of the GATA6 protein (p.Pro91Ser). This variant is present in population databases (rs766886560, gnomAD 0.02%). This missense change has been observed in individual(s) with early onset atrial fibrillation or thoracic aortic aneurysm (PMID: 27756709, 28659821). ClinVar contains an entry for this variant (Variation ID: 404061). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. Experimental studies are conflicting or provide insufficient evidence to determine the effect of this variant on GATA6 function (PMID: 27756709). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
not specified Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Feb 13, 2023 | Variant summary: GATA6 c.271C>T (p.Pro91Ser) results in a non-conservative amino acid change in the encoded protein sequence. Three of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 0.00011 in 204928 control chromosomes. The observed variant frequency is approximately 180 fold of the estimated maximal expected allele frequency for a pathogenic variant in GATA6 causing Pancreatic Agenesis and Congenital Heart Defects phenotype (6.3e-07), strongly suggesting that the variant is benign. c.271C>T has been reported in the literature in an individual with early-onset atrial fibrillation (Tucker_2017) and in a bicuspid aortic valve/thoracic aortic aneurysm patient cohort (Gillis_2017). However, these reports did not provide strong evidence for causality (e.g. co-segregation data) and therefore do not allow conclusions about association of the variant with Pancreatic Agenesis and Congenital Heart Defects. At least one publication reports experimental evidence evaluating an impact on protein function, finding the variant leads to increased transcriptional activity (Tucker_2017), however, these findings do not allow convincing conclusions about the variant effect. Three clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 and cited the variant as likely benign (n=1) and uncertain significance (n=2). Based on the evidence outlined above, the variant was classified as likely benign. - |
Inborn genetic diseases Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Sep 08, 2022 | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at